Evome Medical Technologies Inc. (the “Company” or “Evome”) announced today preliminary annual financial results for the year ending December 31, 2023. Because of a strong fourth quarter, the Company generated positive Adjusted EBITDA for 2023.

Summary of Preliminary Annual Financial Results for 2023

  • Generated annual revenues of $62.6 million
  • Generated annual gross margin of $22.5 million
  • Annual gross margin as percentage of sales of 36%
  • Generated annual Adjusted EBITDA of $852,000

“We can now say with confidence, we have completed the turn-around of this company,” said CEO Mike Seckler. “This past year, 2023, was a tale of two different companies. The first two quarters were frankly calamitous with mounting losses, unserviceable debt and flat or declining revenues. I was brought into the company by the Board at the end of June coinciding with the end of the second quarter. Starting July 1, 2023, the first day of our third quarter, our team focused on increasing sales, cutting costs and restructuring our debt to make it manageable and serviceable. I am very proud of our team at the operating unit level, they understood the gravity of the situation and we worked together to make tough decisions that resulted in two consecutive quarters of positive Adjusted EBITDA. I am pleased with our bankers who worked with our creditors to restructure our debt to give us room to turn this company around. I am also grateful that we had patient creditors that understood and believed in the plan.”

“As our first quarter ends, we continue to make improvements. But rather than working to shore up the company, we are working on several fronts to increase revenues and profits. We are working to reduce debt by divesting non-core business units. We have also launched our RST product and have several orders. We have very strong demand internationally and spent the first quarter retooling our operations to deliver the RST and additional products overseas. We anticipate this will be reflected in improved revenues and margins from the second quarter onward. We also plan to launch the SpaceTek Knee™ product, co-developed by NASA, toward the end of the year. Because we are driving toward a growing and profitable business with a normalized level of debt, we are finding more opportunities to expand our business. I am excited to report our first quarter accomplishments soon. And lastly, I appreciate our shareholders support of me and my plan. I believe we have succeeded in saving this company, now we focus on improving the share price.”

Unless otherwise specified, all financial information is presented in Canadian dollars ("$", "dollars" and "C$") and has been rounded to the nearest hundred thousand. The Company will file its financial statements for the year ended December 31, 2023, and related management discussion and analysis (in the form of an annual report on Form 10-K) on SEDAR+ and with the United States Securities and Exchange Commission on April 16, 2024.

Mike Seckler ‎Chief Executive Officer ‎Tel: 1 (800) 760-6826 ‎Email: Info@Salonaglobal.com‎

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ‎policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ‎release.‎

Certain statements contained in this press release constitute "forward-looking information" within ‎the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities ‎laws. These statements can be identified by the use of forward-looking terminology such as “expects” ‎‎“believes”, “estimates”, "may", "would", "could", ‎‎"should", "potential", ‎‎‎‎‎"will", "seek", "intend", ‎‎"plan", and "anticipate", and similar expressions as they relate ‎‎‎‎to the Company, including: ‎the financial results of 2023; the Company increasing revenues and profits; the Company reducing debt by divesting non-core business units; the Company anticipating improved revenues and margins from the second quarter onward; and the Company launching its SpaceTek Knee™ product toward the end of the year. All ‎statements ‎other than statements of ‎‎historical fact may be forward-looking‎ information. Such statements reflect the Company's current ‎views and intentions with respect to future ‎events, and current information available to the Company, ‎and are subject to certain risks, ‎uncertainties and assumptions, including: the completion of normal quarter and year end accounting procedures and adjustments not resulting in any material differences; the successful launch and sales of Reactive Step Trainer (RST) in Q2 which is a higher margin product then the Company’s existing products; the Company successfully identifying a buyer for a non-core business and negotiating and closing a sale; the Company having the necessary capital to complete its business objectives. The Company cautions that the forward-looking statements contained ‎herein are qualified by important factors that could cause actual results to differ materially from ‎those reflected by such statements. Such factors include but are not limited to the ‎‎general business ‎and ‎‎economic ‎conditions in the regions in ‎which the Company operates; the ability of the Company to ‎execute on key ‎‎priorities, ‎including the successful completion of acquisitions, business‎ retention, and‎‎ ‎strategic plans and to‎‎ attract, develop ‎and retain key executives; difficulty integrating newly acquired ‎businesses; ‎‎ongoing or new disruptions in the supply chain, the extent and scope of such supply chain ‎disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability ‎to‎‎‎ implement business strategies and pursue business opportunities; ‎‎disruptions in or attacks ‎‎(including ‎cyber-attacks) on the Company’s information technology, internet, network access or other ‎‎‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎‎‎‎criminal behavior to which the Company is exposed; the failure of third parties to comply with their ‎obligations to the Company or its ‎affiliates; the‎ impact of new and changes to, or application of, ‎current laws and regulations; ‎granting of permits and licenses in a highly regulated business; the ‎‎overall difficult ‎‎‎‎‎litigation environment, including in the United States; increased competition; changes ‎in foreign currency rates; ‎increased ‎‎‎‎funding ‎costs and market volatility due to market illiquidity and ‎competition for funding; the ‎availability of funds ‎‎‎‎and resources to pursue operations; critical ‎‎accounting estimates and changes to accounting standards, policies,‎‎‎‎ and methods used by the ‎Company; the occurrence of natural and unnatural‎‎ catastrophic ‎events ‎and claims ‎‎‎‎resulting from such ‎events; as well as those risk factors discussed or ‎referred to ‎in the ‎Company’s disclosure ‎documents ‎filed with United States Securities and Exchange Commission ‎and ‎available at ‎www.sec.gov, and with ‎‎the securities regulatory authorities in certain provinces of Canada and ‎‎available at ‎‎www.sedarplus.ca. Should any ‎factor affect the Company in an unexpected manner, or should ‎‎‎assumptions underlying ‎the forward-looking ‎information prove incorrect, the actual results or events ‎may differ ‎‎materially from the results ‎or events predicted. ‎Any such forward-looking information is ‎expressly qualified in its ‎‎entirety by this cautionary ‎statement. Moreover, ‎the Company does not ‎assume responsibility for the accuracy or ‎‎completeness of such ‎forward-looking ‎information. The ‎forward-looking information included in this press release ‎‎is made as of the ‎date of this press ‎release ‎and the Company undertakes no obligation to publicly update or revise ‎‎any forward-‎looking ‎information, ‎other than as required by applicable law‎.‎

Non-GAAP Measures

This press release refers to "Adjusted EBITDA" which is a non-GAAP and non-IFRS financial measure that does ‎not have a standardized meaning prescribed by GAAP or IFRS. The Company’s presentation of this financial ‎measure may not be comparable to similarly titled measures used by other companies. This non-GAAP financial measure assists the Company’s management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition plans that are fundamentally different from the ongoing operating plans of the Company. The Company’s management also believes that presenting this measure allows investors to view the Company’s performance using the same measures that the Company uses in evaluating its financial and business performance and trends. “Adjusted EBITDA” is defined as net operating loss excluding depreciation of property and equipment, amortization of right-of-use asset, amortization of intangible asset, severance expense due to restructuring, and stock-based compensation. The following table provides reconciliation between net operating (loss) and Adjusted EBITDA:‎

  ‎For the year ended‎ December 31, 2023
Net operating (loss) $ (5,544,714 )
Depreciation of property and equipment   1,002,627  
Amortization of right-of-use asset   2,023,956  
Amortization of intangible asset   1,505,108  
Severance Expenses / Restructuring   576,101  
Stock based compensation 1,288,455  
Adjusted EBITDA $ 851,533  
       

Preliminary Financial Metrics

This press release contains certain pre-released financial metrics. The financial metrics contained in this press release are preliminary and represent the most current information available to the Company's management, as financial closing procedures for the fourth quarter and year ended December 31, 2023 are not yet complete. The Company's actual consolidated audited financial statements for such period may result in material changes to the financial metrics summarized in this press release (including by any one financial metric, or all of the financial metrics, being below or above the figures indicated) as a result of the completion of normal quarter and year end accounting procedures and adjustments, and also what one might expect to be in the final consolidated financial statements based on the financial metrics summarized in this press release. Although the Company believes the expectations reflected in this press release are based upon reasonable assumptions, the Company can give no assurance that actual results will not differ materially from these expectations.

Evome Medical Technologies (TSXV:EVMT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Evome Medical Technologies Charts.
Evome Medical Technologies (TSXV:EVMT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Evome Medical Technologies Charts.